Search
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746ApprovedIt is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,[L39491] an X-linked genetic disorder characterized by missing or non-functional … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.
Felodipine
go.drugbank.com/drugs/DB01023ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.
Products: FELODIPIN 2.5MG RET HEU NButyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug. … [L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.
Trifluoperazine
go.drugbank.com/drugs/DB00831ApprovedA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Mixtures: Stelabid No 2, Stelabid No 1Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab is produced by a recombinant cell line cultured by continuous perfusion. … By binding to both the soluble subunit and the membrane-bound precursor of TNF-α [A106], infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α
Products: INFLECTRA 100MG PLV F E KO, REMICADE 100MG PULV F E KOPhenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%Calcium
go.drugbank.com/drugs/DB01373ApprovedInvestigationalNutraceuticalCalcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. … Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day.
Mixtures: Prenatal Vitamin No 53 Iron Fum Folic Acid Docusate CA DHA, UltimateCare ONE NFProducts: AAR OS NZopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081] … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory